Various treatment approaches are available to effectively reduce the risk of osteoporotic fractures. In this context, a therapeutic option recommended by the Swiss Association Against Osteoporosis (SVGO\/ASCO) for very high fracture risk [1] is characterized not only by its dual mechanism of action [2], but also by its exciting history of discovery.<\/p>\n
<\/p>\n
In Switzerland, about 400,000 people, especially women, are affected by the insidious bone disease osteoporosis, which is characterized by the loss of bone substance and increased bone fragility [3]. Thus, one in three women aged 50 years and older suffers an osteoporosis-related fracture, often with drastic health, social, and financial consequences [3, 4]. In addition, the risk of a subsequent fracture doubles with the occurrence of a first fracture and is particularly high immediately thereafter [5].<\/p>\n
Sclerostin antibody romosozumab recommended for very high risk of fracture<\/strong><\/p>\n If there is a very high risk of fracture due to a recent fracture or other risk factors, such as low bone mineral density (BMD), the Swiss Association Against Osteoporosis (SVGO\/ASCO) recommends, among other things, one year of treatment with romosozumab (EVENITY\u00ae) followed by antiresorptive therapy [1]. The monoclonal antibody has been approved since July 2020 for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture [2, 6]. Its efficacy was demonstrated, among others, in the pivotal phase III ARCH trial, in which one year of treatment with romosozumab followed by the antiresorptive alendronate reduced fracture risk significantly more than alendronate monotherapy [7].<\/p>\n Want to learn more about the pivotal ARCH trial?<\/em><\/p>\n Click here
\n here<\/u>
\n<\/a> for a study summary or watch the video below! <\/p>\n